{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:12:44Z","timestamp":1788635564162,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd013365","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000}}],"reference-count":245,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013365.pub2","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T07:35:56Z","timestamp":1631518556000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma"],"prefix":"10.1002","volume":"2021","author":[{"given":"Moritz","family":"Ernst","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Oeser","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Besiroglu","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Caro-Valenzuela","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abd El Aziz","sequence":"additional","affiliation":[{"name":"Department of Surgery; Mayo Clinic; Rochester Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine; University Hospital of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[{"name":"Haematology\/Transfusion Medicine; NHS Blood and Transplant; Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Goldkuhle","sequence":"additional","affiliation":[{"name":"Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"issue":"3 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S314","DOI":"10.1016\/j.bbmt.2019.12.394","article-title":"Senescent\/exhausted phenotype of CAR T cells and induction of immunoregulatory environment correlate with reduced response to CAR T cell therapy in relapsed\/refractory B cell malignancies","volume":"26\u00a0","author":"Beider","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood-2019-128068","article-title":"Upregulation of senescent\/exhausted phenotype of CAR T cells and Induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed\/refractory B cell malignancies","volume":"134","author":"Beider","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD013365.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"e000148","DOI":"10.1136\/jitc-2019-000148","article-title":"Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients","volume":"8","author":"Itzhaki","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"23","key":"10.1002\/14651858.CD013365.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/blood.V126.23.264.264","article-title":"4SCAR19 chimeric antigen receptor-modified T cells as a breakthrough therapy for highly chemotherapy-resistant late-stage B cell lymphoma patients with bulky tumor mass","volume":"126\u00a0","author":"Chang","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD013365.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified t cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"7567","DOI":"10.1200\/JCO.2018.36.15_suppl.7567","article-title":"Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory\/relapsed B-cell non-Hodgkin lymphoma","volume":"36","author":"Gauthier","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"17","key":"10.1002\/14651858.CD013365.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts pfs in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0008|cit8","first-page":"453","article-title":"Biomarker analysis of tisagenlecleucel pre-infusion biopsies of adult patients with relapsed or refractory (r\/r) diffuse large B-cell lymphoma (DLBCL)","volume":"2 (Suppl 2)","author":"Agoulnik","year":"2018","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2019-128302","article-title":"Impact of tisagenlecleucel chimeric antigen receptor (CAR)-T cell therapy product attributes on clinical outcomes in adults with relapsed or refractory diffuse large B-cell lymphoma (r\/r DLBCL)","volume":"134","author":"Bachanova","year":"2019","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0010|cit10","first-page":"347","article-title":"An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r\/r) diffuse large B-cell lymphoma (DLBCL)","volume":"2 (Suppl 2)","author":"Borchmann","year":"2018","journal-title":"HemaSphere"},{"issue":"9","key":"10.1002\/14651858.CD013365.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s10147-020-01699-6","article-title":"Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"25","author":"Goto","year":"2020","journal-title":"International Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013365.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Advances"},{"issue":"4","key":"10.1002\/14651858.CD013365.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Advances"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0014|cit14","first-page":"S20","article-title":"Long-term follow-up of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma: updated analysis of Juliet study","volume":"25\u00a0","author":"Bishop","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.1016\/j.clml.2017.07.213","article-title":"Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (r\/r) diffuse large B-cell lymphoma (DLBCL) - an interim analysis","volume":"Suppl 2","author":"Schuster","year":"2017","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.2437_6","article-title":"Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (r\/r) diffuse large B-cell lymphoma (DLBCL) - an interim analysis","volume":"35\u00a0","author":"Schuster","year":"2017","journal-title":"Hematological Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013365.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013365.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Schuster","year":"2020","journal-title":"Blood Advances"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1016\/j.bbmt.2018.12.326","article-title":"Prolonged Improvement in patient reported quality of life (qol) following tisagenlecleucel infusion in adult patients (pts) with relapsed\/refractory (r\/r) diffuse large B-cell lymphoma (DLBCL): 19-month follow-up (fu) of the Juliet study","volume":"25\u00a0","author":"Tam","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0020|cit20","first-page":"4108","article-title":"Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed\/refractory diffuse large b-cell lymphoma patients in the Juliet trial","volume":"134","author":"Westin","year":"2019","journal-title":"American Society of Hematology"},{"issue":"25","key":"10.1002\/14651858.CD013365.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"4129\u201339","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted t cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1002\/14651858.CD013365.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor\u2013transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD013365.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous t cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with t cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD013365.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013365.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-curation complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor r cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Molecular Therapy"},{"issue":"20","key":"10.1002\/14651858.CD013365.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of b-lineage cells and regression of lymphoma in a patient treated with autologous t cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1002\/14651858.CD013365.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/hon.128_2629","article-title":"Safety of lisocabtagene maraleucel given with durvalumab in patients with relapsed\/refractory aggressive B cell non Hodgkin lymphoma: first results from the Platform study","volume":"37\u00a0","author":"Siddiqi","year":"2019","journal-title":"Hematological Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood-2019-127640","article-title":"Combination of anti-CD19 and anti-CD20 chimeric antigen receptor t cells for relapsed and refractory diffuse large B cell lymphoma: an open-label, single-arm, phase \u2160\/\u2161 trial","volume":"134","author":"Sang","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1182\/blood-2019-127640","article-title":"Combination of anti-CD19 and anti-CD20 chimeric antigen receptor t cells for relapsed and refractory diffuse larger B cell lymphoma: an open-label, single-arm, phase I\/II trial","volume":"134","author":"Sang","year":"2019","journal-title":"Blood"},{"issue":"16","key":"10.1002\/14651858.CD013365.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor t cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Medicine"},{"issue":"16","key":"10.1002\/14651858.CD013365.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1002\/cam4.3259","article-title":"Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor t cells for relapsed and refractory diffuse large B cell lymphoma","volume":"9","author":"Sang","year":"2020","journal-title":"Cancer Medicine"},{"issue":"17 Suppl 6","key":"10.1002\/14651858.CD013365.pub2-BIB0034|cit34","first-page":"2545","article-title":"Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas","volume":"21","author":"Levine","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0035|cit35","unstructured":"Phase IIa study of redirected autologous T cells engineered to contain anti-CD19 attached to TCRz and 4-signaling domains in patients with chemotherapy relapsed or refractory CD19+ lymphomas clinicaltrials.gov\/show\/nct02030834"},{"issue":"26","key":"10.1002\/14651858.CD013365.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor t cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD013365.pub2-BIB0037|cit37","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety & long term clinical outcomes in Transcend NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hon.2437_127","article-title":"High CR rates in relapsed\/ refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (transcend NHL 001)","volume":"35","author":"Abramson","year":"2017","journal-title":"Hematological Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hon.2437_127","article-title":"High CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T cell product JCAR017 (Transcend NHL 001)","volume":"35\u00a0","author":"Abramson","year":"2017","journal-title":"Hematological Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0041|cit41","first-page":"215","article-title":"Safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (Liso-cel) in relapsed\/refractory (R\/R) large B-cell lymphoma (LBCL)","volume":"43\u00a0","author":"Abramson","year":"2020","journal-title":"Oncology Research and Treatment"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1200\/JCO.2017.35.15_suppl.7513","article-title":"Cr rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001)","volume":"35","author":"Abramson","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"10254","key":"10.1002\/14651858.CD013365.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2019-127508","article-title":"Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed\/refractory (R\/R) large B cell lymphomas","volume":"134","author":"Abramson","year":"2019","journal-title":"Blood"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0046|cit46","first-page":"S25","article-title":"High durable CR rates and preliminary safety profile for JCAR017 in R\/R aggressive b-NHL (TRANSCEND NHL 001 study): a defined composition CD19-directed CAR T-cell product with potential for outpatient administration","volume":"24","author":"Abramson","year":"2018","journal-title":"Transplantation and Cellular Therapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0047|cit47","first-page":"579","article-title":"Characterization of cytokine release syndrome and neurological events in the phase 1 transcend NHL 001 trial of lisocabtagene maraleucel for patients with relapsed\/refractory large B-cell lymphoma","volume":"4\u00a0","author":"Palomba","year":"2020","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood-2019-127145","article-title":"Impact of lisocabtagene maraleucel (liso-cel) treatment on health-related quality of life and health utility in patients (pts) with relapsed\/refractory (R\/R) aggressive B cell non-hodgkin lymphoma (NHL): Transcend NHL 001","volume":"134","author":"Patrick","year":"2019","journal-title":"Blood"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/JCO.2018.36.5_suppl.122","article-title":"Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R\/R aggressive B-NHL (TRANSCEND NHL 001 study)","volume":"36","author":"Siddiqi","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2018-99-115769","article-title":"Efficacy and safety of JWCAR029 in adult patients with relapsed and refractory B-cell non-hodgkin lymphoma","volume":"132","author":"Yan","year":"2018","journal-title":"Blood"},{"issue":"23","key":"10.1002\/14651858.CD013365.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"6995","DOI":"10.1158\/1078-0432.CCR-19-0101","article-title":"Clinical efficacy and tumor microenvironment influence in a dose-escalation study of anti-CD19 chimeric antigen receptor t cells in refractory B-cell non-hodgkin's lymphoma","volume":"25","author":"Yan","year":"2019","journal-title":"Clinical Cancer Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1182\/blood-2019-127751","article-title":"Clinical response in relapsed\/refractory (R\/R) B-NHL treated with the CD19-directed CAR T-Cell product JWCAR029","volume":"134","author":"Ying","year":"2019","journal-title":"Blood"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1016\/j.bbmt.2018.12.653","article-title":"Commercial chimeric antigen receptor (CAR) T cells: unfamiliar roads and stalled cars","volume":"25\u00a0","author":"Byrne","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2017.35.15_suppl.3025","article-title":"Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)","volume":"35","author":"Galon","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"14 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1158\/1538-7445.AM2016-CT135","article-title":"Updated phase I results from ZUMA-1: a phase I-II multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"76","author":"Ghobadi","year":"2016","journal-title":"Cancer Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0056|cit56","first-page":"86","article-title":"Early biomarker correlates of severe neurologic events and cytokine release syndrome in ZUMA-1, a multicenter trial evaluating axicabtagene ciloleucel in refractory aggressive non-Hodgkin lymphoma","volume":"5","author":"Locke","year":"2017","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0057|cit57","first-page":"590","article-title":"Retreatment of patients with refractory large B cell lymphoma with axicabtagene ciloleucel (Axi-cel) in ZUMA-1","volume":"4\u00a0","author":"Locke","year":"2020","journal-title":"HemaSphere"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0058|cit58","first-page":"83","article-title":"Axicabtagene ciloleucel (axi-cel) in patients with refractory large B cell lymphoma: durability of response in Zuma-1","volume":"2\u00a0","author":"Locke","year":"2018","journal-title":"HemaSphere"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1200\/JCO.2018.36.15_suppl.3003","article-title":"Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (pts) with refractory large B cell lymphoma","volume":"36","author":"Locke","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013365.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0061|cit61","first-page":"348","article-title":"Axicabtagene ciloleucel (axi-cel) in patients with refractory large B cell lymphoma: outcomes by prior lines of therapy in Zuma-1","volume":"2\u00a0","author":"Locke","year":"2018","journal-title":"HemaSphere"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1200\/JCO.2018.36.15_suppl.3039","article-title":"Outcomes by prior lines of therapy (lot) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B cell lymphoma","volume":"36","author":"Locke","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"7512","DOI":"10.1200\/JCO.2017.35.15_suppl.7512","article-title":"Clinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL)","volume":"35","author":"Locke","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0064|cit64","first-page":"172","article-title":"Clinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; Kte-c19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"102","author":"Locke","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0065|cit65","first-page":"172","article-title":"Clinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; Kte-c19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"102\u00a0","author":"Locke","year":"2017","journal-title":"Haematologica"},{"issue":"13 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"CT019","DOI":"10.1158\/1538-7445.AM2017-CT019","article-title":"Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"77","author":"Locke","year":"2017","journal-title":"Cancer Research"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013365.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"VI359","DOI":"10.1093\/annonc\/mdw378.02","article-title":"Ongoing complete remissions in phase 1 of ZUMA-1: a phase 1-2 multi-center study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in patients with refractory aggressive B cell non-Hodgkin lymphoma (NHL)","volume":"27","author":"Locke","year":"2016","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013365.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Molecular Therapy"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2017.35.15_suppl.3023","article-title":"Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)","volume":"35","author":"Locke","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1200\/JCO.2017.35.15_suppl.3023","article-title":"Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with Axicabtagene Ciloleucel (axi-cel)","volume":"35","author":"Locke","year":"2017","journal-title":"Journal of Clinical oncology"},{"issue":"13 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"CT020","DOI":"10.1158\/1538-7445.AM2017-CT020","article-title":"Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19)","volume":"77","author":"Locke","year":"2017","journal-title":"Cancer Research"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.bbmt.2018.12.148","article-title":"2-year follow-up and high-risk subset analysis of Zuma-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients with refractory large B cell lymphoma","volume":"25\u00a0","author":"Neelapu","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"22","key":"10.1002\/14651858.CD013365.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood.V128.22.998.998","article-title":"Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B-cell lymphoma (DLBCL): results from the pivotal phase 2 Zuma-1","volume":"128","author":"Neelapu","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hon.2437_7","article-title":"Axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphomas (NHL): primary results of the pivotal trial ZUMA-1","volume":"35","author":"Neelapu","year":"2017","journal-title":"Hematological Oncology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hon.2437_7","article-title":"Axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphomas (NHL): primary results of the pivotal trial ZUMA-1","volume":"35\u00a0","author":"Neelapu","year":"2017","journal-title":"Hematological Oncology"},{"issue":"26","key":"10.1002\/14651858.CD013365.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013365.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"VI325","DOI":"10.1093\/annonc\/mdw375.38","article-title":"ZUMA-1: a phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"27\u00a0","author":"Neelapu","year":"2016","journal-title":"Annals of Oncology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0078|cit78","first-page":"333","article-title":"ZUMA-1 pivotal phase 2 trial of axicabtagene ciloleucel (axi-cel, KTE-C19; Anti-CD19 CAR T cells) in patients (pts) with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"25","author":"Neelapu","year":"2017","journal-title":"Molecular Therapy"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0079|cit79","first-page":"333","article-title":"ZUMA-1 pivotal phase 2 trial of axicabtagene ciloleucel (axi-cel, KTE-C19; Anti-CD19 CAR T cells) in patients (pts) with refractory aggressive non-Hodgkin lymphoma (NHL)","volume":"25\u00a0","author":"Neelapu","year":"2017","journal-title":"Molecular Therapy"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/hon.2438_132","article-title":"Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel)","volume":"35\u00a0","author":"Neelapu","year":"2017","journal-title":"Hematological Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013365.pub2-BIB0081|cit81","first-page":"117","article-title":"An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma","volume":"15","author":"Neelapu","year":"2017","journal-title":"Clinical Advances in Hematology & Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2019-127094","article-title":"Peak lymphocyte count after CAR T infusion is a clinically accessible test that correlates with clinical response in axicabtagene ciloleucel therapy for lymphoma","volume":"134","author":"Novo","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD013365.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/2159-8290.CD-NB2017-009","article-title":"DLBCL responds well to anti-CD19 CAR therapy","volume":"7","author":"Rose","year":"2017","journal-title":"Cancer Discovery"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0084|cit84","first-page":"86","article-title":"Tumor microenvironment immune gene signature associated with axicabtagene ciloleucel (axi-cel, KTE-C19), an anti-CD19 chimeric antigen receptor (CAR) T cell, in a multicenter trial (ZUMA-1)","volume":"5","author":"Rossi","year":"2017","journal-title":"Journal for ImmunoTherapy of Cancer"},{"issue":"13 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0085|cit85","first-page":"LJ","article-title":"Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA- 1","volume":"78","author":"Rossi","year":"2018","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0086|cit86","first-page":"318","article-title":"Updated results from Zuma-1: a phase 1-2 multicenter study evaluating the safety and efficacy of kte-c19 (anti-CD19 car T cells) in refractory aggressive B-cell non-Hodgkin lymphoma (NHL)","volume":"101","author":"Siddiqi","year":"2016","journal-title":"Haematologica"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1016\/j.bbmt.2018.12.314","article-title":"End of phase 1 results from Zuma-6: axicabtagene ciloleucel (axi-cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma","volume":"25\u00a0","author":"Jacobson","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of phase 1 results from ZUMA-6: axicabtagene ciloleucel (axi-cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0089|cit89","unstructured":"Safety and efficacy of KTE-C19 in combination with atezolizumab in adults with refractory diffuse large B-cell lymphoma (DLBCL) clinicaltrials.gov\/show\/NCT02926833"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013365.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/hon.124_2629","article-title":"Phase I clinical trial of CD19-targeted 19-28z\/4-1bbl \"armored\" car T cells in patients with relapsed or refractory NHL and CLL including richter transformation","volume":"37\u00a0","author":"Batlevi","year":"2019","journal-title":"Hematological Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013365.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1479-5876-11-160","article-title":"Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (dli) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I\/II-trial","volume":"11","author":"Buhmann","year":"2013","journal-title":"Journal of Translational Medicine"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Frontiers in Oncology"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0093|cit93","unstructured":"A clinical trial of anti-CD30 CAR-T cell therapy chictr.org.cn\/showprojen.aspx?proj=15360"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood-2019-131078","article-title":"Outcomes in aggressive B-cell non-Hodgkin lymphomas with anti-CD19 CAR T-cell (CTL019) products not meeting commercial release specifications","volume":"134","author":"Chong","year":"2019","journal-title":"Blood"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jcyt.2020.03.011","article-title":"Clinical outcomes for anti-CD19 CAR T cell (CTL019) products not meeting commercial release specifications","volume":"22\u00a0","author":"Chong","year":"2020","journal-title":"Cytotherapy"},{"issue":"24","key":"10.1002\/14651858.CD013365.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"S295","DOI":"10.1016\/S1525-0016(16)33556-0","article-title":"A clinical trial using third generation CD19 targeting CAR T cells for relapsed lymphoma and leukemia","volume":"1","author":"Enblad","year":"2016","journal-title":"Molecular Therapy"},{"issue":"23","key":"10.1002\/14651858.CD013365.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood.V126.23.1534.1534","article-title":"Third generation CD19-CAR T cells for relapsed and refractory lymphoma and leukemia report from the Swedish phase I\/IIa trial","volume":"126\u00a0","author":"Enblad","year":"2015","journal-title":"Blood"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0099|cit99","first-page":"1534","article-title":"CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia-report from the Swedish phase I\/IIa trial","volume":"4","author":"Enblad","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD013365.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/s41375-019-0476-y","article-title":"Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed\/refractory B cell non-Hodgkin lymphoma","volume":"33","author":"Jain","year":"2019","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2018-99-111711","article-title":"Patient-reported and neurocognitive outcomes in patients treated with axicabtagene ciloleucel","volume":"132","author":"Jim","year":"2018","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0102|cit102","unstructured":"CD19 CAR T cells for B cell malignancies after allogeneic transplant clinicaltrials.gov\/show\/NCT01475058"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0103|cit103","unstructured":"Study of ACTR087 in subjects with relapsed or refractory B-cell lymphoma clinicaltrials.gov\/show\/NCT02776813"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0104|cit104","unstructured":"Study of ACTR707 in combination with rituximab in subjects with relapsed or refractory B cell lymphoma clinicaltrials.gov\/show\/NCT03189836"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0105|cit105","unstructured":"CAR-T for R\/R B-NHL clinicaltrials.gov\/ct2\/show\/NCT03196830"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0106|cit106","unstructured":"Long-term follow-up study for patients previously treated with a Juno CAR T-cell product clinicaltrials.gov\/show\/NCT03436771"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0107|cit107","unstructured":"CAR CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood NK cells, high-dose chemotherapy, and stem cell transplant in treating participants with B-cell lymphoma clinicaltrials.gov\/show\/NCT03579927"},{"issue":"21","key":"10.1002\/14651858.CD013365.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V124.21.677.677","article-title":"Interim safety analysis: a phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28Z CAR-T) directed against CD19+ B-cells for relapsed and refractory aggressive B cell non-Hodgkin lymphoma (B-NHL)","volume":"124","author":"Sauter","year":"2014","journal-title":"Blood"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD013365.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"vi194","DOI":"10.1093\/neuonc\/noy148.807","article-title":"Clinical neurological features and electrographic patterns of patients with relapsed or refractory large B-cell lymphoma treated with axicabtagene ciloleucel at Memorial Sloan Kettering Cancer Center (MSKCC)","volume":"20\u00a0","author":"Sequeira","year":"2018","journal-title":"Neuro-Oncology"},{"issue":"11","key":"10.1002\/14651858.CD013365.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/ajh.25951","article-title":"Commercial anti-CD19 CAR T cell therapy for patients with relapsed\/refractory aggressive B cell lymphoma in a European center","volume":"95","author":"Sesques","year":"2020","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD013365.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood.2019002920","article-title":"Long-term outcomes of sleeping beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas","volume":"135","author":"Srour","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD013365.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clinical Immunology"},{"issue":"24","key":"10.1002\/14651858.CD013365.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1002\/14651858.CD013365.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1182\/blood.V126.23.930.930","article-title":"Phase I studies of cellular immunotherapy using central memory derived-CD19-specific T cells following autologous stem cell transplantation for patients with high-risk intermediate grade B-lineage non-Hodgkin lymphoma","volume":"126\u00a0","author":"Popplewell","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1002\/14651858.CD013365.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0116|cit116","unstructured":"An open-label, single-center and single-arm clinical study of sequential infusion of anti-CD22 and anti-CD19 CAR-T cells for patients with relapsed or refractory B-cell malignancies who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-OPN-16008526"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2018-99-113714","article-title":"CAR22\/19 cocktail therapy for patients with refractory\/relapsed B-cell malignancies","volume":"132","author":"Huang","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD013365.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0119|cit119","unstructured":"CD19-targeted CAR-T cell therapy for MRD of B-cell lymphoma chictr.org.cn\/showproj.aspx?proj=15018"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0120|cit120","unstructured":"An open label, single center, single arm clinical study for sequential infusion of anti-CD19 CAR-T and anti-CD22 CAR-T therapy following autologous hematopoietic stem cell transplantation (auto-HSCT) for relapsed, refractory and high-risk B cell lymphoma chictr.org.cn\/com\/25\/historyversionpuben.aspx?regno=ChiCTR-OPN-16009847"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0121|cit121","unstructured":"A single-center, single-arm, open-label, dose escalation study to evaluate the safety & preliminary anti-tumor activity of CD19 single-chain antibody chimeric antigen receptor T cells (CAR-T-19) for the treatment of patients with relapsed\/refractory B-cell leukemia\/lymphoma chictr.org.cn\/showproj.aspx?proj=22440"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0122|cit122","unstructured":"Memory-enriched CAR-T cells immunotherapy for B cell lymphoma (MeCAR) clinicaltrials.gov\/ct2\/show\/NCT02652910"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0123|cit123","unstructured":"CD19-redirected autologous cells (CAR-CD19 t cells) clinicaltrials.gov\/ct2\/show\/NCT02933775"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0124|cit124","unstructured":"A phase 1 study evaluating safety and efficacy of C-CAR011 treatment in DLBCL subjects clinicaltrials.gov\/ct2\/show\/NCT02976857"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0125|cit125","unstructured":"Treatment of relapsed and\/or chemotherapy refractory B-cell malignancy by tandem CAR T cells targeting CD19 and CD20 clinicaltrials.gov\/ct2\/show\/NCT03097770"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0126|cit126","unstructured":"XLCART001 treatment in relapsed\/refractory\/high-risk B-cell malignancy subjects clinicaltrials.gov\/ct2\/show\/NCT03598179"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0127|cit127","unstructured":"A single arm, open-label, multi-centre, phase I\/II study evaluating the safety and clinical activity of AUTO3, a CAR T cell treatment targeting CD19 and CD22 and consolidation with anti PD-1 antibodies clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2016-004682-11"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0128|cit128","unstructured":"CD19\/22 CAR t cells (AUTO3) for the treatment of diffuse large B cell lymphoma clinicaltrials.gov\/show\/NCT03287817"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0129|cit129","unstructured":"Tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma clinicaltrials.gov\/show\/NCT03570892"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0130|cit130","unstructured":"Phase II open label trial to determine safety & efficacy of tisagenlecleucel in pediatric non-Hodgkin lymphoma patients clinicaltrials.gov\/show\/NCT03610724"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0131|cit131","unstructured":"Anti-CD19 CAR-T cell therapy for relapsed and refractory CD19-positive lymphoma chictr.org.cn\/showproj.aspx?proj=29929"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0132|cit132","unstructured":"Evaluation of CAR19 T-cells as an optimal bridge to allogeneic transplantation clinicaltrials.gov\/show\/NCT02431988"},{"issue":"2","key":"10.1002\/14651858.CD013365.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"e034629","DOI":"10.1136\/bmjopen-2019-034629","article-title":"Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a tlr2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)","volume":"10\u00a0","author":"George","year":"2020","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0134|cit134","unstructured":"CD19-CART01 in pediatric patients affected by relapsed\/refractory CD19+ acute lymphoblastic leukemia and non Hodgkin lymphoma who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2017-002088-16-IT"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0135|cit135","unstructured":"A phase 2 multicenter, open-label, single-arm study of KTE-C19 in Japanese patients with refractory or relapsed large B cell lymphoma clinicaltrials.jp\/user\/showCteDetailE.jsp?japicId=JapicCTI-183914"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0136|cit136","unstructured":"Pilot study of redirected autologous T cells engineered to contain humanized anti-CD19 in patients with relapsed or refractory CD19+ leukemia and lymphoma previously treated with cell therapy clinicaltrials.gov\/show\/NCT02374333"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0137|cit137","unstructured":"T cells expressing a fully-human antiCD19 chimeric antigen receptor for treating B-cell malignancies clinicaltrials.gov\/show\/NCT02659943"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0138|cit138","unstructured":"JCAR014 and durvalumab in treating patients with relapsed or refractory B-cell non-Hodgkin lymphoma clinicaltrials.gov\/show\/NCT02706405"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0139|cit139","unstructured":"Study evaluating the efficacy and safety with CAR-T for recurrent or refractory diffuse large B cell lymphoma clinicaltrials.gov\/show\/NCT02728882"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0140|cit140","unstructured":"The sequential therapy of CD19-targeted and CD20-targeted CAR-T cell therapy for diffuse large B cell lymphoma (DLBCL) clinicaltrials.gov\/show\/NCT02737085"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0141|cit141","unstructured":"PCAR-119 bridge immunotherapy prior to stem cell transplant in treating patients with CD19 positive leukemia and lymphoma clinicaltrials.gov\/show\/NCT02892695"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0142|cit142","unstructured":"CD19\/CD22 chimeric antigen receptor T cells and chemotherapy in treating patients with recurrent or refractory CD19 positive diffuse large B-cell lymphoma or B acute lymphoblastic leukemia clinicaltrials.gov\/show\/NCT03233854"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0143|cit143","unstructured":"A phase I\/II study to evaluate the safety of cellular immunotherapy using autologous T cells engineered to express a CD20-specific chimeric antigen receptor for patients with relapsed or refractory B cell non-Hodgkin lymphomas clinicaltrials.gov\/show\/NCT03277729"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0144|cit144","unstructured":"Assessment of safety and efficacy of IM19 for relapsed or refractory NHL patients clinicaltrials.gov\/show\/NCT03528421"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0145|cit145","unstructured":"CD19-specific T cells post alloSCT clinicaltrials.gov\/show\/NCT03579888"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0146|cit146","unstructured":"Safety and efficacy of axicabtagene ciloleucel in combination with utomilumab in adults with refractory large B-cell lymphoma clinicaltrials.gov\/show\/NCT03704298"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0147|cit147","unstructured":"Human CD19 targeted t cells injection (CD19 CAR-T) therapy for relapsed and refractory CD19-positive lymphoma clinicaltrials.gov\/show\/NCT03720457"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0148|cit148","unstructured":"A study of CC-97540, CD19-targeted NEX-T chimeric antigen receptor (CAR) T cells, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma clinicaltrials.gov\/show\/NCT04231747"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0149|cit149","unstructured":"CD19 CAR-T expressing IL7 and CCL19 combined with PD1 mAb for relapsed or refractory diffuse large B cell lymphoma clinicaltrials.gov\/show\/NCT04381741"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0150|cit150","unstructured":"CLBR001 and SWI019 in patients with relapsed refractory B-cell malignancies clinicaltrials.gov\/show\/NCT04450069"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0151|cit151","unstructured":"Study of tisagenlecleucel in Chinese adult patients with relapsed or refractory diffuse large B-cell non-Hodgkin lymphoma (DLBCL) clinicaltrials.gov\/show\/NCT04456023"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0152|cit152","unstructured":"19(T2)28z1xx chimeric antigen receptor (CAR) T cells in people with B-cell cancers clinicaltrials.gov\/show\/NCT04464200"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0153|cit153","unstructured":"An exploratory clinical trial of autologous humanized anti-cluster of differentiation antigen 19\/20(CD19\/CD20) dual specific CAR-T cells Injection clinicaltrials.gov\/show\/NCT04486872"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0154|cit154","unstructured":"Phase 1 study of autologous CD30.CAR-T in relapsed or refractory CD30 positive non-Hodgkin lymphoma clinicaltrials.gov\/show\/NCT04526834"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0155|cit155","unstructured":"Anti-CD19 chimeric antigen receptor T cells for treatment of relapsed or refractory non-Hodgkin lymphoma clinicaltrials.gov\/show\/NCT04545762"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0156|cit156","unstructured":"Study of tisagenlecleucel in combination with pembrolizumab in R\/R diffuse large B-cell lymphoma patients clinicaltrials.gov\/show\/NCT03630159"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2018-99-113744","article-title":"Early response data for pediatric patients with non-Hodgkin lymphoma treated with CD19 chimeric antigen receptor (CAR) T-cells","volume":"132","author":"Rivers","year":"2018","journal-title":"Blood"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013365.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"8515","DOI":"10.1200\/jco.2015.33.15_suppl.8515","article-title":"Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CART) posthigh dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel\/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL)","volume":"33","author":"Sauter","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013365.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood.2018883421","article-title":"CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"134","author":"Sauter","year":"2019","journal-title":"Blood"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013365.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.bbmt.2018.12.146","article-title":"Clinical results of a first-in-human phase 1 study of point-of-care manufactured bispecific anti-CD19, anti-CD20 chimeric antigen receptor modified t (CAR-20.19-T) cells for relapsed, refractory, non-Hodgkin lymphoma (NHL)","volume":"25\u00a0","author":"Shah","year":"2019","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0161|cit161","unstructured":"A safety trial of lisocabtagene maraleucel (JCAR017) for relapsed and refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting clinicaltrials.gov\/show\/NCT03744676"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0162|cit162","unstructured":"Lisocabtagene maraleucel (JCAR017) as second-line therapy (TRANSCEND-NHL-006) clinicaltrials.gov\/show\/NCT03483103"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0163|cit163","unstructured":"TRANSCEND WORLD a phase 2, single-arm, multi-cohort, multi-center trial to determine the efficacy and safety of JCAR017 in adult subjects with aggressive B-cell non-Hodgkin lymphoma (TRANSCEND WORLD) clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-000106-38"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0164|cit164","unstructured":"TRANSFORM a global randomized multicenter phase 3 trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (TRANSFORM) clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2018-000929-32"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0165|cit165","unstructured":"A study to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas clinicaltrials.gov\/show\/NCT03575351"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0166|cit166","unstructured":"Axicabtagene ciloleucel expanded access study (ZUMA-9) clinicaltrials.gov\/show\/NCT03153462"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0167|cit167","unstructured":"Safety and efficacy of axicabtagene ciloleucel in combination with either rituximab or lenalidomide in participants with refractory large B-cell lymphoma (ZUMA-14) clinicaltrials.gov\/show\/NCT04002401"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0168|cit168","unstructured":"A phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in subjects with relapsed\/refractory diffuse large B cell lymphoma (ZUMA-7) clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-002261-22"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0169|cit169","unstructured":"A study evaluating the effectiveness of axicabtagene ciloleucel versus standard of care therapy in subjects with diffuse large B cell lymphoma returning after, or resistant to, initial treatment clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2017-002261-22"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0170|cit170","unstructured":"Efficacy of axicabtagene ciloleucel compared to standard of care therapy in subjects with relapsed\/refractory diffuse large B cell lymphoma clinicaltrials.gov\/show\/NCT03391466"},{"issue":"5","key":"10.1002\/14651858.CD013365.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"22","key":"10.1002\/14651858.CD013365.pub2-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1182\/blood.V128.22.4192.4192","article-title":"Transcend NHL 001: Immunotherapy with the CD19-directed CAR T-Cell product JCAR017 results in high complete response rates in relapsed or refractory B-Cell non-Hodgkin lymphoma","volume":"128","author":"Abramson","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1002\/14651858.CD013365.pub2-BIB0173|cit173","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMc1712460","article-title":"More on Anti-CD19 CAR T Cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abramson","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"4","key":"10.1002\/14651858.CD013365.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mco.2020.2103","article-title":"Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: a meta-analysis","volume":"13","author":"Al-Mansour","year":"2020","journal-title":"Molecular and Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD013365.pub2-BIB0176|cit176","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00134-020-06193-1","article-title":"Acute life-threatening toxicity from CAR T-cell therapy","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Medicine"},{"issue":"19","key":"10.1002\/14651858.CD013365.pub2-BIB0177|cit177","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1001\/jama.2017.15218","article-title":"FDA approval of tisagenlecleucel: promise and complexities of a $475 000 cancer drug","volume":"318","author":"Bach","year":"2017","journal-title":"JAMA"},{"issue":"27","key":"10.1002\/14651858.CD013365.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"8745","key":"10.1002\/14651858.CD013365.pub2-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/0140-6736(91)92513-2","article-title":"AIDS-associated non-Hodgkin lymphoma","volume":"337","author":"Beral","year":"1991","journal-title":"Lancet"},{"issue":"19","key":"10.1002\/14651858.CD013365.pub2-BIB0180|cit180","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1055\/a-0853-4689","article-title":"Immuno-oncology meets intensive care cedicine: CAR-T cells","volume":"144","author":"B\u00f6ll","year":"2019","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"2","key":"10.1002\/14651858.CD013365.pub2-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy","volume":"3","author":"Borrega","year":"2019","journal-title":"Hemasphere"},{"issue":"7","key":"10.1002\/14651858.CD013365.pub2-BIB0182|cit182","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3238\/PersOnko.2018.02.16.07","article-title":"CAR-T-Zell-Therapie: Aussichten und Risiken","volume":"115","author":"Buchholz","year":"2018","journal-title":"Deutsches \u00c4rzteblatt International"},{"issue":"11","key":"10.1002\/14651858.CD013365.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1182\/blood.V106.11.750.750","article-title":"Development of a measure of health-related quality of life for non-Hodgkin\u2019s lymphoma clinical research: the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)","volume":"106","author":"Cella","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD013365.pub2-BIB0184|cit184","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"10.1002\/14651858.CD013365.pub2-BIB0185|cit185","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013365.pub2-BIB0186|cit186","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/blood-2007-01-070300","article-title":"Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index","volume":"110","author":"Chung","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD013365.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1002\/14651858.CD013365.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0189|cit189","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0190|cit190","unstructured":"What study designs can be considered for inclusion in an EPOC review and what should they be called? EPOC Resources for review authors, 2017 epoc.cochrane.org\/resources\/epoc-resources-review-authors"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0191|cit191","unstructured":"European Medicines Agency (EMA) First two CAR-T cell medicines recommended for approval in the European Union www.ema.europa.eu\/en\/news\/first-two-car-t-cell-medicines-recommended-approval-european-union"},{"issue":"1","key":"10.1002\/14651858.CD013365.pub2-BIB0192|cit192","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","article-title":"Relapsed\/refractory diffuse large B-cell lymphoma","volume":"2011","author":"Friedberg","year":"2011","journal-title":"ASH Education Program Book"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0193|cit193","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0194|cit194","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1177\/1060028020944233","article-title":"Axicabtagene ciloleucel: clinical data for the use of CAR T-cell therapy in relapsed and refractory large B-cell lymphoma","volume":"55","author":"Halford","year":"2020","journal-title":"Annals of Pharmacotherapy."},{"key":"10.1002\/14651858.CD013365.pub2-BIB0195|cit195","doi-asserted-by":"crossref","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020), Cochrane 2020 Available from training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0196|cit196","unstructured":"Higgins JPT Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane 2020 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0197|cit197","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"346","author":"Husereau","year":"2013","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0198|cit198","unstructured":"Institute for Clinical and Economic Review Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value www.icer-review.org\/wp-content\/uploads\/2017\/07\/ICER_CAR_T_Final_Evidence_Report_032318.pdf"},{"issue":"27","key":"10.1002\/14651858.CD013365.pub2-BIB0199|cit199","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1200\/JCO.19.02103.","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013365.pub2-BIB0200|cit200","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00277-018-3368-8","article-title":"The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review","volume":"97","author":"Jin","year":"2018","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/978-3-319-13150-4_11","article-title":"Management of diffuse large B-cell lymphoma (DLBCL)","volume":"165","author":"Kubuschok","year":"2015","journal-title":"Cancer Treatment and Research"},{"issue":"2","key":"10.1002\/14651858.CD013365.pub2-BIB0202|cit202","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0203|cit203","unstructured":"Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane 2020 Available from training.cochrane.org\/handbook"},{"issue":"23","key":"10.1002\/14651858.CD013365.pub2-BIB0204|cit204","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0205|cit205","unstructured":"Li T Higgins JPT Deeks JJ Chapter 5: Collecting data. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane 2020 Available from training.cochrane.org\/handbook"},{"issue":"5","key":"10.1002\/14651858.CD013365.pub2-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1002\/14651858.CD013365.pub2-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1182\/blood.V128.22.4204.4204","article-title":"Post relapse survival rates in diffuse large B-cell lymphoma","volume":"128","author":"McMillan","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1002\/14651858.CD013365.pub2-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"issue":"27","key":"10.1002\/14651858.CD013365.pub2-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"26","key":"10.1002\/14651858.CD013365.pub2-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0211|cit211","volume-title":"SEER Cancer Statistics Review, 1975-2015","author":"Noone","year":"2018"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0212|cit212","unstructured":"Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice www.novartis.com\/news\/media-releases\/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019"},{"issue":"5","key":"10.1002\/14651858.CD013365.pub2-BIB0213|cit213","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD013365.pub2-BIB0214|cit214","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"5","key":"10.1002\/14651858.CD013365.pub2-BIB0215|cit215","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncology"},{"issue":"303","key":"10.1002\/14651858.CD013365.pub2-BIB0216|cit216","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Science Translational Medicine"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0217|cit217","doi-asserted-by":"crossref","unstructured":"Reeves BC Deeks JJ Higgins JPT Shea B Tugwell P Wells GA Cochrane Non-Randomized Studies of Interventions Methods Group Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane 2020 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604.ch24"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0218|cit218","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"11","key":"10.1002\/14651858.CD013365.pub2-BIB0219|cit219","first-page":"1862","article-title":"Report of the committee on Hodgkin's disease staging procedures","volume":"31","author":"Rosenberg","year":"1971","journal-title":"Cancer Research"},{"issue":"25","key":"10.1002\/14651858.CD013365.pub2-BIB0220|cit220","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013365.pub2-BIB0221|cit221","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncology"},{"issue":"15","key":"10.1002\/14651858.CD013365.pub2-BIB0222|cit222","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0223|cit223","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings tables' and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane 2020 Available from training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0224|cit224","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"308","author":"Schuster","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0225|cit225","unstructured":"Shemilt I Mugford M Byford S Drummond M Eisenstein E Knapp M Chapter 15: Incorporating economics evidence. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0226|cit226","unstructured":"Sterne JA Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0228|cit228","volume-title":"World Cancer Report 2014","author":"Stewart","year":"2014"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0229|cit229","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"issue":"6","key":"10.1002\/14651858.CD013365.pub2-BIB0230|cit230","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"14","key":"10.1002\/14651858.CD013365.pub2-BIB0231|cit231","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1200\/JCO.2006.10.5957","article-title":"Lymphoma in older patients","volume":"25","author":"Thieblemont","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0232|cit232","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD013365.pub2-BIB0233|cit233","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0234|cit234","unstructured":"FDA approves axicabtagene ciloleucel for large B-cell lymphoma www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm581296.htm"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0235|cit235","unstructured":"FDA approves tisagenlecleucel for adults with relapsed or refractory large B-cell lymphoma www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm606540.htm"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0236|cit236","unstructured":"FDA approves new treatment for adults with relapsed or refractory large-B-cell lymphoma www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-adults-relapsed-or-refractory-large-b-cell-lymphoma"},{"issue":"11","key":"10.1002\/14651858.CD013365.pub2-BIB0237|cit237","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1093\/annonc\/mdu109","article-title":"Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era","volume":"25","author":"Vaidya","year":"2014","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013365.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V80.8.2142.2142","article-title":"Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up","volume":"80","author":"Vose","year":"1992","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD013365.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"8","key":"10.1002\/14651858.CD013365.pub2-BIB0240|cit240","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/annonc\/mdf189","article-title":"Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"13","author":"Weidmann","year":"2002","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0241|cit241","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1007\/s00520-020-05774-6","article-title":"Health-related quality of life measured using EQ-5D in patients with lymphomas","volume":"29","author":"Xu","year":"2020","journal-title":"Supportive Care in Cancer"},{"issue":"7","key":"10.1002\/14651858.CD013365.pub2-BIB0242|cit242","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1007\/s12325-020-01397-9","article-title":"A review of two regulatory approved anti-CD19 CAR T-cell therapies in diffuse large B-cell lymphoma: why are indirect treatment comparisons not feasible?","volume":"37","author":"Zhang","year":"2020","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD013365.pub2-BIB0243|cit243","doi-asserted-by":"publisher","first-page":"1924379","DOI":"10.1155\/2020\/1924379","article-title":"CAR-T cell therapy in cancer: tribulations and road ahead","volume":"2020","author":"Zhang","year":"2020","journal-title":"Journal of Immunology Research"},{"issue":"9","key":"10.1002\/14651858.CD013365.pub2-BIB0244|cit244","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.3324\/haematol.2016.147256","article-title":"Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"issue":"6","key":"10.1002\/14651858.CD013365.pub2-BIB0245|cit245","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013365","article-title":"Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma","author":"Goldkuhle","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T03:34:22Z","timestamp":1771904062000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013365.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":245,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013365.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]}}}